+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials



The safety profile of dalfampridine extended release in multiple sclerosis clinical trials



Clinical Therapeutics 34(5): 1056-1069



Dalfampridine (fampridine outside the United States) is a broad-spectrum potassium channel blocker. Dalfampridine extended-release tablets have been approved by the US Food and Drug Administration to improve walking in patients with multiple sclerosis (MS). The objective of this article is to review the safety profile of dalfampridine extended-release tablets with respect to its expected use in patients with MS. We reviewed published data relevant to patient safety profiles based on searches of articles in PubMed published up to December 31, 2010, using the search terms fampridine OR dalfampridine OR 4-aminopyridine AND (multiple sclerosis) in combination with toxicity, safety, clinical trial, pharmacokinetics, and seizures. These searches were supplemented with data derived from the approved package insert and relevant sections of the New Drug Application (22-250) as submitted to the US Food and Drug Administration. The literature searches returned 58 unique citations, of which 26 were considered relevant for characterizing the safety profile of dalfampridine; excluded citations were as follows: reviews (19), evaluation of 3,4-diaminopyridine (4), intravenous dosing (2), inadequate information on patient doses (2), preclinical models (2), and "other" (3). Dalfampridine is nearly completely (approximately 96%) eliminated unchanged in urine, with limited transformation to 2 inactive metabolites and low risk for interaction with drugs metabolized by hepatic P450 cytochromes. However, in patients with renal impairment (creatinine clearance [CrCl], ≤80 mL/min), mean peak plasma concentrations were 68%-101% higher and apparent clearance was 43%-73% lower relative to those without impairment, precluding dalfampridine use in patients with moderate (CrCl, 30-50 mL/min) or severe renal impairment (CrCl, <30 mL/min). Dalfampridine has a narrow therapeutic range. At the therapeutic dose of 10 mg twice daily, adverse events were generally mild to moderate and, consistent with the mechanism of action of dalfampridine, were primarily related to stimulatory effects on the nervous system. A thorough QT study suggested a low risk of induction of QT prolongation and associated cardiac arrhythmias in healthy individuals at therapeutic (10 mg, twice daily) or supratherapeutic (30 mg, twice daily) doses. Although the incidence of seizures was dose related, data from the clinical trials of dalfampridine extended-release tablets suggest that the risk of seizure at the therapeutic dose, in patients with no history of seizure, is not likely to be higher than background rates in MS. In patients with MS, dalfampridine has a narrow therapeutic range but an acceptable safety profile when used at the therapeutic dose of 10 mg twice daily.

(PDF emailed within 0-6 h: $19.90)

Accession: 036379693

Download citation: RISBibTeXText

PMID: 22497693

DOI: 10.1016/j.clinthera.2012.03.007


Related references

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug, Healthcare and Patient Safety 7: 169-174, 2016

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29(12): 1627-1636, 2014

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2: 53-64, 2019

Dalfampridine extended release: in multiple sclerosis. Cns Drugs 24(10): 883-891, 2010

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology 68(4): 494-502, 2010

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis 21(10): 1322-1331, 2016

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7: 229-239, 2011

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. International Journal of Ms Care 17(3): 138-145, 2015

Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5(4): 199-204, 2012

A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple Sclerosis. International Journal of Ms Care 18(4): 170-176, 2016

Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. Journal of Managed Care and Specialty Pharmacy 23(7): 771-780, 2018

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Therapeutics and Clinical Risk Management 11: 1-7, 2015

PND50 Estimation of the Effect of Dalfampridine Extended Release on Health Utility in Patients With Multiple Sclerosis Using Two Equations for Mapping the MSWS-12 to the EQ-5D. Value in Health 15(7): A554-A555, 2012

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis. Clinicoeconomics and Outcomes Research 8: 177-186, 2016

A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. International Journal of Ms Care 16(3): 153-160, 2014